Eleven Biotherapeutics
Eleven Biotherapeutics
Eleven Biotherapeutics

Investor Relations

Eleven Biotherapeutics designs and develops novel therapeutics for ocular diseases using its AMP-Rx™ protein engineering platform.

We create a new breed of potent and selective ophthalmic proteins. Eleven is creating a pipeline of engineered protein drugs for ocular diseases that are rationally designed for improved biological and drug-like properties.

  • Our differentiated ophthalmic protein products are designed for therapeutic impact in the ocular space. Eleven has a proprietary pipeline of product candidates for the treatment of ocular disease. Our products are engineered to treat both front-of-the-eye and back-of-the-eye diseases in new and effective ways.
  • Our technology enables innovative protein therapeutics. Eleven's proprietary protein engineering technology opens the potential to modulate key molecular targets responsible for the initiation or maintenance of an ocular disease.
  • EBI-005, Eleven's lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in clinical development as one of the first topically administered proteins for the treatment of inflammatory diseases at the surface of the eye.
NASDAQ: EBIO
Price:
10.54
Change:
+ 0.05
Day High:
10.61
Day Low:
10.00
Volume:
26,800
4:00 PM ET on October 24, 2014
Delayed at least 20 minutes.
Media Contact:
Gina Nugent
The Yates Network
617-460-3579